Close
Close

lirilumab (CAT#: TAB-757)

Datasheet
DESCRIPTION CATALOG # SIZE PRICE
Anti-KIRD2 subgroup Recombinant Antibody TAB-757 1mg Please Inquiry

PRODUCT INFORMATION

  • Product Overview
  • Recombinant human monoclonal antibody expressed in CHO binding to human KIRD2 subgroup. Lirilumab is a human monoclonal antibody designed for the treatment of cancer.
  • Target
  • KIRD2 subgroup
  • Type
  • IgG4 - kappa
  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Species Reactivity
  • Human
  • Expression Host
  • CHO
  • Applications
  • Suitable for use in Neut, ELISA, IF, IP, FuncS, FC, ICC and most other immunological methods.
  • CAS
  • 1000676-41-4
  • Predicted N terminal
  • QVQLVQSG
  • Molecular Weight
  • 145.2 kDa
  • Purity
  • >95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
  • Size
  • 1mg
  • Storage
  • Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.

BACKGROUND

  • Introduction
  • KIRs are human natural killer (NK) cell receptors for MHC class I molecules. Most inhibit the activity of NK cells thus preventing cell lysis. Two main families of receptors for HLA class I have been discovered on human NK cells: Killer cell Immunoglobulin-like receptors (KIR) and CD94/NKG2 heterodimers. The KIR receptors are an extremely diverse family of receptors. In addition to receptors for HLA, NK cells also express pattern recognition receptors e.g. TLRs and Nod proteins.
  • Antigen Description
  • Human KIRD2 subgroup (killer cell Immunoglobulin-like Receptor subgroup, including KIR2DL1 (nkat1/CD158A), KIR2DL2 (nkat6/CD158B1), KIR2DL3 (nkat2/CD158B2), KIR2DS1 (CD158H) and KIR2DS2 -nkat5/CD158J-)
  • Keywords
  • Killer-cell immunoglobulin-like receptors; KIRs; KIR2DL1/2/3

Customer reviews and Q&As    

Related Products
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2024 Creative Biolabs. | Contact Us